Veliparib is being developed as an improvement on previous drugs, for the treatment of advanced or metastatic non-squamous non-small cell lung cancer. In combination with carboplatin and paclitaxel it will, if licenced, offer an additional treatment option for patients with this indication.
Veliparib (ABT-888) with carboplatin and paclitaxel for advanced or metastatic non-squamous (current or former smokers) non-small cell lung cancer
Interventions:
Carboplatin (Paraplatin)
, Paclitaxel (Taxol; paclitaxel albumin)
, Veliparib (ABT-888; NSC 737664)
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2017